Merck & Company Inc (MRK)vsTriSalus Life Sciences Inc. (TLSI)
MRK
Merck & Company Inc
$150.38
+3.93%
HEALTHCARE · Cap: $368.89B
TLSI
TriSalus Life Sciences Inc.
$3.89
+11.78%
HEALTHCARE · Cap: $233.98M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 149373% more annual revenue ($67.38B vs $45.08M). MRK leads profitability with a 3.6% profit margin vs -62.6%. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
TLSI
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$150.38
$65.72 premium
Intrinsic value data unavailable for TLSI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
No standout strengths identified
Areas to Watch
Trading at 8.9x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
1.7% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 35.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : TLSI
TLSI has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : TLSI
The primary concerns for TLSI are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 5.26 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while TLSI is a turnaround play — different risk/reward profiles.
TLSI carries more volatility with a beta of 0.47 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 18/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical firm at the forefront of enhancing cancer therapy through its proprietary localized drug delivery systems, which significantly improve the effectiveness of immuno-oncology agents. The company is strategically addressing the complexities of tumor microenvironments with a robust pipeline of clinical programs aimed at advancing treatment options in oncology. With a commitment to expanding patient access to transformative therapies, TriSalus is well-positioned to drive meaningful change in cancer care, aligning with the growing demand for advanced, effective cancer treatments. The company’s initiatives underscore its potential to be a key player in the rapidly evolving oncology landscape, attracting interest from both investors and healthcare stakeholders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?